Test directory: Chromogranin A

Ordering Code 6736
Test Name Chromogranin A
Preferred Specimen Serum
Preferred Container SST (Gold)
Other Specimen/Container Serum in Plain (Red)
Optimum Volume 1.5 mL
Handling Instructions Separate serum promptly.
Transport Requirements Oahu: Ambient
Airline: Frozen
Specimen Stability Ambient: 48 Hours
Refrigerated: 3 Days
Frozen: 3 Months
Stability after separation from cells
Rejection Criteria Plasma
Avail. Stat NO
Analytic Time 8 Days
Methodology Immunofluorescence
Reference Lab  ARUP Laboratories

Reference range(s)

The reference ranges listed below are valid on this date of June 1, 2025.
Component Age Male Norm Male Critical Low Male Critical High Female Norm Female Critical High Female Critical Low Units Add'l info
Chromogranin A ALL 0-187 0-187 ng/mL

This test is...
This test is performed using the BRAHMS CGA II
Kryptor kit. Results obtained with different methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease and should be evaluated in combination with clinical symptoms, diagnostic evidence, and/or other laboratory parameters. The change of CgA concentration over time provides diagnostic information whether a tumor progression has occurred

An increase of CgA serum concentrations of more than 50% to a value of greater than 100 ng/ml between consecutive monitoring visits defines a positive test result, representing a higher probability that a tumor progression has occurred

A change of CgA serum concentrations of equal or less than 50% increase between monitoring visits or to a value of 100 ng/ml or less defines a negative test result, representing a lower probability that a tumor progression has occurred
Nontumor related elevations of Chromogranin A can be observed in gastrointestinal, cardiovascular, and renal disorders, cancers other than neuroendocrine tumors, as well as with proton pump inhibitor (PPI) therapy. It is recommended to stop PPI treatment for at least 14 days prior to testing
Note1

Note1:


This test is performed using the BRAHMS CGA II
Kryptor kit. Results obtained with different methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease and should be evaluated in combination with clinical symptoms, diagnostic evidence, and/or other laboratory parameters. The change of CgA concentration over time provides diagnostic information whether a tumor progression has occurred

An increase of CgA serum concentrations of more than 50% to a value of greater than 100 ng/ml between consecutive monitoring visits defines a positive test result, representing a higher probability that a tumor progression has occurred

A change of CgA serum concentrations of equal or less than 50% increase between monitoring visits or to a value of 100 ng/ml or less defines a negative test result, representing a lower probability that a tumor progression has occurred
Nontumor related elevations of Chromogranin A can be observed in gastrointestinal, cardiovascular, and renal disorders, cancers other than neuroendocrine tumors, as well as with proton pump inhibitor (PPI) therapy. It is recommended to stop PPI treatment for at least 14 days prior to testing
.